CHMP news: Izba, Tritanrix, sc RoActemra, laquinimod
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has this month recommended for approval Alcon Laboratories' prostaglandin analog Izba (travoprost) to treat ocular hypertension and open-angle glaucoma and the subcutaneous version of Roche's rheumatoid arthritis treatment RoActemra (tocilizumab).